Clinical trial results:
A phase 3 randomised non-inferiority trial to evaluate the use of imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

Summary

EudraCT number	2012-005696-14
Trial protocol	GB
Global end of trial date	16 September 2016

Results information

Result version number	v1 (current)
This version publication date	18 December 2019
First version publication date	18 December 2019
Summary attachment (see zip file)	File Note - Study Withdrawn (06451 - File Note - SPIRIT 3 - Study withdrawn.pdf)

Trial information

Trial identification

Sponsor protocol code	6451

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	The Newcastle upon Tyne Hospitals NHS Foundation Trust
Sponsor organisation address	Level 1, Regent Point, Regent Farm Road, Newcastle upon Tyne, United Kingdom, NE3 3HD
Public contact	Professor Stephen O'Brien, Newcastle University, 0044 0191 282 0904, stephen.o'brien@ncl.ac.uk
Scientific contact	Professor Stephen O'Brien, Newcastle University, 0044 0191 282 0904, stephen.o'brien@ncl.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 September 2016
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	16 September 2016
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The study aims to see if treatment with imatinib is as good as treatment with nilotinib when patients in either group who are not doing so well switch to ponatinib. The response to treatment is measured in the blood and tests will look for leukaemic cells.

Protection of trial subjects:

This study was terminated prior to the recruitment of any participants, therefore no results are available. As a result, where '9999999' is entered this means the data point is N/A.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 September 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 9999999
Worldwide total number of subjects	9999999
EEA total number of subjects	9999999

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	9999999
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The protocol stated that patients would be screened for eligibility to take part in the trial. Screening assessments included: Demography, CML diagnosis, medical history, concomitant medication, haematology, biochemistry, blood glucose, physical examination and Blood Pressure measurement.

Pre-assignment period milestones

Number of subjects started	9999999
Number of subjects completed	9999999

Period 1

Period 1 title	Treatment (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Imatinib

Arm description: -

Arm type	Experimental
Investigational medicinal product name	imatinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

400mg daily (taken OD)

Arm title	nilotinib

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Nilotinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

600mg daily (taken as 300mg BD)

Number of subjects in period 1	Imatinib	nilotinib
Started	6666666	3333333
Completed	6666666	3333333

Baseline characteristics

End points

End points reporting groups

Reporting group title	Imatinib
Reporting group description: -	
Reporting group title	nilotinib
Reporting group description: -	

Primary: Major molecular response (MMR)

End point title	Major molecular response (MMR)[1]

End point description:

This study was terminated prior to the recruitment of any participants, therefore no end point data was collected. As a result, where '9999999' is entered this means the data point is N/A.

End point type	Primary

End point timeframe:

Major molecular response (MMR) at 3 years on trial

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This study was terminated prior to the recruitment of any participants, therefore no end point data is available. As a result, where '9999999' is entered within the EudraCT report, this means the data point is N/A.

End point values	Imatinib	nilotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0[2]	0[3]		
Units: %				

Notes:

[2] - Study terminated prior to the recruitment of any participants, therefore no end point data available

[3] - Study terminated prior to the recruitment of any participants, therefore no end point data available

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]

Timeframe for reporting adverse events:

This study was terminated prior to the recruitment of any participants, therefore no results are available and no adverse events were reported. As a result, where '9999999' is entered this means the data point is N/A.

Assessment type	Systematic

Dictionary used

Dictionary name	Protocol
Dictionary version	2

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: This study was terminated prior to the recruitment of any participants, therefore no AEs were reported. As a result, where '9999999' is entered this means the data point is N/A.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 January 2016	Protocol amendment to update cardiovascular safety profile. To incorporate another TKI (dasatinib) into the trial design as a first line treatment. To include the TKI bosutinib as an option for participants who do not tolerate their first line medication. To make changes and additions to the participant-facing documentation. (Following submission of this amendment, the trial was later terminated before recruitment was initiated).

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported